MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461665 | Name: Escitalopram
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.

Chemical Structure

Escitalopram
Escitalopram
CAS#128196-01-0 (free base)

Theoretical Analysis

MedKoo Cat#: 461665

Name: Escitalopram

CAS#: 128196-01-0 (free base)

Chemical Formula: C19H18FN2O

Exact Mass: 309.1403

Molecular Weight: 309.36

Elemental Analysis: C, 73.77; H, 5.86; F, 6.14; N, 9.06; O, 5.17

Price and Availability

Size Price Availability Quantity
25mg USD 350.00 2 Weeks
50mg USD 650.00 2 Weeks
100mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
128196-01-0 (free base) 219861-08-2 (oxalate)
Synonym
Escitalopram; Seroplex; (S)-Citalopram; S(+)-Citalopram; S-(+)-Citalopram; (+)-Citalopram; Esertia; Esitol
IUPAC/Chemical Name
(S)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
InChi Key
WSEQXVZVJXJVFP-FQEVSTJZSA-N
InChi Code
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
SMILES Code
N#CC1=CC2=C([C@@](C3=CC=C(F)C=C3)(CCCN(C)C)OC2)C=C1
Appearance
Oil
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
A selective serotonin reuptake inhibitor.
In vitro activity:
Escitalopram inhibited 5-HTT functions approximately 2 times more potently than citalopram and at least 40 times more potently than R-citalopram. Reference: Psychopharmacology (Berl). 2003 Jun;167(4):353-62. https://pubmed.ncbi.nlm.nih.gov/12719960/
In vivo activity:
After 6 weeks of escitalopram treatment, chronic stress maintained a significant decrease in the percentage of sucrose preference as compared to the control group in the stress exposed group (81.13 ± 7.49 vs. 49.84 ± 4.09, p < 0.001). Escitalopram treatment, either the 5 mg/kg b.w. dose or the up-titration to 10 mg/kg b.w regimen, determined an antidepressant effect and significantly increased the sucrose preference percentage in comparison to the stress rat group (78.44 ± 9.04 vs. 49.84 ± 4.09, p < 0.001 and 84.39 ± 6.34 vs. 49.84 ± 4.09, p < 0.001, respectively) (Figure 1B). Reference: Int J Mol Sci. 2021 Jul 13;22(14):7483. https://pubmed.ncbi.nlm.nih.gov/34299103/
Solvent mg/mL mM
Solubility
DMSO 33.0 106.67
DMSO:PBS (pH 7.2) (1:1) 0.5 1.62
DMF 25.0 80.81
Ethanol 20.0 64.65
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 309.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Sánchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. doi: 10.1007/s00213-002-1364-z. Epub 2003 Apr 26. PMID: 12719960. 2. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001 Aug;29(8):1102-9. PMID: 11454728. 3. Dionisie V, Ciobanu AM, Toma VA, Manea MC, Baldea I, Olteanu D, Sevastre-Berghian A, Clichici S, Manea M, Riga S, Filip GA. Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress. Int J Mol Sci. 2021 Jul 13;22(14):7483. doi: 10.3390/ijms22147483. PMID: 34299103; PMCID: PMC8304451. 4. Perez-Caballero L, Soto-Montenegro ML, Desco M, Mico JA, Berrocoso E. Sustained escitalopram administration affects glucose metabolism in the rat brain. Eur Neuropsychopharmacol. 2021 May 19;51:1-6. doi: 10.1016/j.euroneuro.2021.04.016. Epub ahead of print. PMID: 34022746.
In vitro protocol:
1. Sánchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. doi: 10.1007/s00213-002-1364-z. Epub 2003 Apr 26. PMID: 12719960. 2. von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001 Aug;29(8):1102-9. PMID: 11454728.
In vivo protocol:
1. Dionisie V, Ciobanu AM, Toma VA, Manea MC, Baldea I, Olteanu D, Sevastre-Berghian A, Clichici S, Manea M, Riga S, Filip GA. Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress. Int J Mol Sci. 2021 Jul 13;22(14):7483. doi: 10.3390/ijms22147483. PMID: 34299103; PMCID: PMC8304451. 2. Perez-Caballero L, Soto-Montenegro ML, Desco M, Mico JA, Berrocoso E. Sustained escitalopram administration affects glucose metabolism in the rat brain. Eur Neuropsychopharmacol. 2021 May 19;51:1-6. doi: 10.1016/j.euroneuro.2021.04.016. Epub ahead of print. PMID: 34022746.
1: Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Review. PubMed PMID: 24424469; PubMed Central PMCID: PMC4047306. 2: Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):121-8. doi: 10.1517/17425255.2014.863873. Epub 2013 Nov 30. Review. PubMed PMID: 24289655. 3: Kim JM, Bae KY, Stewart R, Jung BO, Kang HJ, Kim SW, Shin IS, Hong YJ, Kim JH, Shin HY, Kang G, Ahn Y, Kim JK, Jeong MH, Yoon JS. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. J Clin Psychiatry. 2015 Jan;76(1):62-8. doi: 10.4088/JCP.14m09281. PubMed PMID: 25375836. 4: Wang Y, Zhang H, Chai F, Liu X, Berk M. The effects of escitalopram on myocardial apoptosis and the expression of Bax and Bcl-2 during myocardial ischemia/reperfusion in a model of rats with depression. BMC Psychiatry. 2014 Dec 4;14:349. doi: 10.1186/s12888-014-0349-x. PubMed PMID: 25471226; PubMed Central PMCID: PMC4259089. 5: Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, Lacy BE, DiBaise JK, Prather CM, Abraham BP, El-Serag HB, Moayyedi P, Herrick LM, Szarka LA, Camilleri M, Hamilton FA, Schleck CD, Tilkes KE, Zinsmeister AR. Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology. 2015 Aug;149(2):340-9.e2. doi: 10.1053/j.gastro.2015.04.020. Epub 2015 Apr 25. PubMed PMID: 25921377; PubMed Central PMCID: PMC4516571. 6: Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med. 2015 Oct;12(10):2036-48. doi: 10.1111/jsm.12980. Epub 2015 Aug 31. PubMed PMID: 26331383. 7: Chang M, Tybring G, Dahl ML, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014 Sep;53(9):801-11. doi: 10.1007/s40262-014-0162-1. Review. PubMed PMID: 25154506. 8: Bishop JR, Najjar F, Rubin LH, Guter SJ, Owley T, Mosconi MW, Jacob S, Cook EH. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54. doi: 10.1097/FPC.0000000000000173. PubMed PMID: 26313485; PubMed Central PMCID: PMC4591203. 9: Li H, Li T, Li G, Luo J. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials. Ann Clin Psychiatry. 2014 Nov;26(4):281-7. PubMed PMID: 25401715. 10: Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015 Feb;37(1):90-7. doi: 10.1097/FTD.0000000000000101. PubMed PMID: 24887634; PubMed Central PMCID: PMC4297217. 11: Findling RL, Robb A, Bose A. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. J Child Adolesc Psychopharmacol. 2013 Sep;23(7):468-80. doi: 10.1089/cap.2012.0023. PubMed PMID: 24041408; PubMed Central PMCID: PMC3779002. 12: Maity N, Ghosal MK, Gupta A, Sil A, Chakraborty S, Chatterjee S. Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Indian J Pharmacol. 2014 Jul-Aug;46(4):433-7. doi: 10.4103/0253-7613.135959. PubMed PMID: 25097285; PubMed Central PMCID: PMC4118540. 13: Diem SJ, Joffe H, Larson JC, Tsai JN, Guthrie KA, LaCroix AZ, Ensrud KE, Freeman EW, Leder BZ. Effects of escitalopram on markers of bone turnover: a randomized clinical trial. J Clin Endocrinol Metab. 2014 Sep;99(9):E1732-7. doi: 10.1210/jc.2014-2288. Epub 2014 Jul 11. PubMed PMID: 25014001; PubMed Central PMCID: PMC4154080. 14: Ji Y, Schaid DJ, Desta Z, Kubo M, Batzler AJ, Snyder K, Mushiroda T, Kamatani N, Ogburn E, Hall-Flavin D, Flockhart D, Nakamura Y, Mrazek DA, Weinshilboum RM. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014 Aug;78(2):373-83. doi: 10.1111/bcp.12348. PubMed PMID: 24528284; PubMed Central PMCID: PMC4137829. 15: Waade RB, Hermann M, Moe HL, Molden E. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol. 2014 Aug;70(8):933-40. doi: 10.1007/s00228-014-1696-8. Epub 2014 May 27. PubMed PMID: 24858822. 16: Hoare J, Carey P, Joska JA, Carrara H, Sorsdahl K, Stein DJ. Escitalopram treatment of depression in human immunodeficiency virus/acquired immunodeficiency syndrome: a randomized, double-blind, placebo-controlled study. J Nerv Ment Dis. 2014 Feb;202(2):133-7. doi: 10.1097/NMD.0000000000000082. PubMed PMID: 24469525. 17: Schreffler SM, Marraffa JM, Stork CM, Mackey J. Sodium channel blockade with QRS widening after an escitalopram overdose. Pediatr Emerg Care. 2013 Sep;29(9):998-1001. doi: 10.1097/PEC.0b013e3182a314b7. PubMed PMID: 24201980. 18: Soczynska JK, Ravindran LN, Styra R, McIntyre RS, Cyriac A, Manierka MS, Kennedy SH. The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: results from a randomized controlled trial. Psychiatry Res. 2014 Dec 15;220(1-2):245-50. doi: 10.1016/j.psychres.2014.06.053. Epub 2014 Jul 10. PubMed PMID: 25124683. 19: Nemoto K, Mihara K, Nakamura A, Nagai G, Kagawa S, Suzuki T, Kondo T. Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients. Pharmacopsychiatry. 2014 May;47(3):101-4. doi: 10.1055/s-0034-1372644. Epub 2014 Apr 24. PubMed PMID: 24764200. 20: Pettersson R, Näslund J, Nilsson S, Eriksson E, Hagsäter SM. Acute escitalopram but not contextual conditioning exerts a stronger "anxiogenic" effect in rats with high baseline "anxiety" in the acoustic startle paradigm. Psychopharmacology (Berl). 2015 Apr;232(8):1461-9. doi: 10.1007/s00213-014-3783-z. Epub 2014 Nov 25. PubMed PMID: 25417552.